An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called Gan & Lee has started the first human test (a Phase 1 trial) in the U.S. of a new obesity drug called ASC36. This is an early-stage study, which mainly checks whether the drug is safe and how the body handles it, rather than proving it helps with weight loss. The news is that the trial has officially begun recruiting or dosing people in the United States. ASC36 is an oral peptide that acts like amylin, a natural hormone that helps control appetite and digestion. In plain terms, peptides are small proteins that can mimic signals the body uses. Amylin is released by the pancreas alongside insulin and helps you feel full, slows how fast your stomach empties, and reduces the spikes in blood sugar after meals. By copying amylin’s effects, ASC36 aims to reduce appetite and support weight loss. The notable thing here is that ASC36 is taken by mouth; many peptide drugs need injections, so an oral format is meant to be more convenient. Because this is a Phase 1 trial, the research right now is limited. Phase 1 studies typically involve a small number of healthy volunteers or people with the condition and focus on safety, tolerability, and basic measures like blood levels of the drug. They don’t prove long-term benefit or how much weight someone will lose. The announcement says the trial has started but doesn’t report results yet, so we don’t know whether ASC36 is effective or how big any weight loss might be. Any claims of benefit would be premature until later-stage trials. This matters because obesity is common and current drugs aren’t perfect for everyone. An oral amylin-mimic could appeal to people who want a pill instead of injections. If ASC36 proves safe and effective in later trials, it could add another option for managing appetite and weight. Investors, clinicians, and people living with obesity will be watching to see whether this drug can offer meaningful weight loss and how it compares to existing treatments. There are important caveats. Phase 1 trials can show that a drug is safe in the short term for a few people, but they don’t guarantee long-term safety or benefit. Peptide drugs can cause side effects like nausea, digestive upset, or low blood sugar, depending on how they work, and we don’t yet have ASC36’s side effect profile. Also, regulatory approval will require larger and longer studies. Until peer-reviewed results and later-stage trials appear, it’s too early to assume ASC36 will be effective or widely available. Bottom line: Gan & Lee has started early human testing of ASC36, an oral drug that mimics the appetite hormone amylin—interesting progress, but real answers about safety and weight-loss benefit are still down the road.
Source: finance.biggo.com